Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00094861 |
|
Recruitment Status :
Completed
First Posted : October 27, 2004
Results First Posted : March 6, 2014
Last Update Posted : March 14, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Dysphagia Non-Small Cell Lung Cancer Lung Cancer | Drug: Palifermin Drug: Placebo Radiation: Radiotherapy Drug: Paclitaxel Drug: Carboplatin | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 100 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2 Study to Evaluate the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) in the Reduction of Dysphagia in Patients Receiving Concurrent Chemoradiotherapy Followed by Consolidation Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Study Start Date : | January 2005 |
| Actual Primary Completion Date : | December 2007 |
| Actual Study Completion Date : | January 2014 |
| Arm | Intervention/treatment |
|---|---|
|
Placebo Comparator: Placebo
Participants received a single intravenous (IV) dose of placebo administered 3 days before the initiation of concurrent chemo/radiotherapy, then once weekly during Weeks 1 through 6, typically for a total of 7 doses. Concurrent radio/chemotherapy was given as follows:
Participants subsequently received two 21-day cycles of consolidation chemotherapy with paclitaxel 225 mg/m^2 and carboplatin dosed at AUC 6.0. |
Drug: Placebo Radiation: Radiotherapy Drug: Paclitaxel Drug: Carboplatin |
|
Experimental: Palifermin
Participants received a single IV dose of palifermin at 180 μg/kg administered 3 days before the initiation of concurrent chemo/radiotherapy, then once weekly during Weeks 1 through 6, typically for a total of 7 doses. Concurrent radio/chemotherapy (administered for 6 to 7 weeks) was given as follows:
Participants subsequently received two 21-day cycles of consolidation chemotherapy with paclitaxel 225 mg/m^2 and carboplatin dosed at AUC 6.0. |
Drug: Palifermin
Other Names:
Radiation: Radiotherapy Drug: Paclitaxel Drug: Carboplatin |
- Number of Participants With Grade 2 or Higher Dysphagia [ Time Frame: Start of treatment through Week 16 ]
Participants underwent acute dysphagia assessments twice weekly during Weeks 1 through 7, and twice weekly thereafter (Weeks 8 through 12) and once weekly after Week 12 until dysphagia resolved to grade ≤ 1 but not beyond Week 16. Dysphagia (difficulty swallowing) was graded using the Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0) dysphagia scale according to the following:
Grade 1: Symptomatic, able to eat regular diet; Grade 2: Symptomatic and altered eating/swallowing (e.g., altered dietary habits, oral supplements), IV fluids indicated <24 hours; Grade 3: Symptomatic and severely altered eating/swallowing (e.g., inadequate oral caloric or fluid intake), IV fluids, tube feedings, or total parenteral nutrition (TPN) indicated ≥24 hours; Grade 4: Life-threatening consequences (e.g., obstruction, perforation).
- Duration of Grade 2 or Higher Dysphagia [ Time Frame: Start of treatment through Week 16 ]
Duration of grade 2 or higher dysphagia was calculated in days from the onset (first occurrence of grade ≥ 2) to the resolution (grade ≤ 1 after the last grade ≥ 2) of dysphagia.
Participants with no assessments were assumed as having grade ≥ 2 dysphagia and with a duration of the mean duration of all participants.
- Maximal Dysphagia Grade [ Time Frame: Start of treatment through Week 16 ]
The mean maximal grade of dysphagia for each participant during the study. Dysphagia (difficulty swallowing) was graded using the Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0) dysphagia scale according to the following:
Grade 1: Symptomatic, able to eat regular diet; Grade 2: Symptomatic and altered eating/swallowing (e.g., altered dietary habits, oral supplements), IV fluids indicated <24 hours; Grade 3: Symptomatic and severely altered eating/swallowing (e.g., inadequate oral caloric or fluid intake), IV fluids, tube feedings, or total parenteral nutrition (TPN) indicated ≥24 hours; Grade 4: Life-threatening consequences (e.g., obstruction, perforation).
- Number of Participants With Severe (Grade 3 or Higher) Dysphagia [ Time Frame: Start of treatment through Week 16 ]
Participants underwent acute dysphagia assessments twice weekly during Weeks 1 through 7, and twice weekly thereafter (Weeks 8 through 12) and once weekly after Week 12 until dysphagia resolved to grade ≤ 1 but not beyond Week 16. Dysphagia (difficulty swallowing) was graded using the Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0) dysphagia scale according to the following:
Grade 1: Symptomatic, able to eat regular diet; Grade 2: Symptomatic and altered eating/swallowing (e.g., altered dietary habits, oral supplements), IV fluids indicated <24 hours; Grade 3: Symptomatic and severely altered eating/swallowing (e.g., inadequate oral caloric or fluid intake), IV fluids, tube feedings, or total parenteral nutrition (TPN) indicated ≥24 hours; Grade 4: Life-threatening consequences (e.g., obstruction, perforation).
- Number of Participants With Unplanned Breaks in Radiotherapy [ Time Frame: Week 1 to Week 6 ]The number of participants with unplanned breaks in radiotherapy of ≥ 5 days or who discontinued radiotherapy during Week 1 to Week 6.
- Maximal Eastern Cooperative Oncology Group (ECOG) Performance Status Increase [ Time Frame: Baseline through Week 12 ]
Maximal increase from Baseline in Eastern Cooperative Oncology Group (ECOG) performance status. ECOG is a scale to assess how a patient's disease is progressing, how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis.
Grade 0: Fully active, able to carry on all pre-disease performance without restriction; Grade 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; Grade 2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours; Grade 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; Grade 4: Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair; Grade 5: Dead.
- Number of Participants Hospitalized [ Time Frame: Baseline to Week 16 ]
- Maximal Body Weight Loss [ Time Frame: Baseline through Week 12 ]Maximal weight loss observed from Baseline through to Week 12.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with a histologically or cytologically proven diagnosis of NSCLC
- Unresectable (locally advanced) stage IIIa or IIIb disease
- Initial radiotherapy field of treatment to encompass greater than or equal to 30% of the esophagus
- Life expectancy greater than or equal to 6 months
- Estimated weight loss less than or equal to 10% in the 3 months before study randomization
- Measurable disease
- 18 years of age or older
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2
- Hemoglobin (hgb) greater than or equal to 10 g/dL without transfusional support or growth factor use in the 4 weeks before study randomization
- Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L without growth factor use in the 2 weeks before study randomization
- Platelet count greater than or equal to 100 x 10^9/L
- Serum bilirubin less than or equal to 1.5 x institutional upper limit of normal (ULN)
- Serum creatinine less than or equal to 2.0 mg/dL (Note: Patients with a serum creatinine greater than or equal to 1.4 and less than or equal to 2.0 mg/dL must demonstrate a 24-hour urinary creatinine clearance greater than or equal to 50 mL/min)
- Females of childbearing potential: negative serum or urine pregnancy test
- Patient must give written informed consent before participating in any study-specific procedure, randomization, or receiving investigational product.
- Patients with reproductive capability must agree to practice adequate contraception methods.
Exclusion Criteria:
- Metastatic disease (M1)/stage 4 NSCLC
- Pleural or pericardial effusion greater than 100 ml in volume as documented by appropriate imaging (positron emission tomography [PET], computed tomography [CT] scan or ultrasound). If an effusion greater than 100 ml is documented by cytology to be free from malignancy and the investigator feels the patient is capable of receiving chemo/radiotherapy for their primary disease/ NSCLC, the investigator should discuss the patient with the study physician at Amgen. Effusions smaller than 100 ml would be acceptable, unless the investigator suspects that the effusion is malignant, in which case the effusions should be evaluated by cytology. Sponsor approval must be obtained before patient is randomized.
- Plan to remove the tumor surgically before completing the protocol chemo/radiotherapy course
- Shielding of any part of the esophagus during radiotherapy (including posterior spinal cord shielding)
- Prior chemotherapy, radiotherapy, or surgery for NSCLC
- Prior invasive malignancy during the past 3 years other than non-melanomatous skin cancer. Note: Patients with prior surgically-cured malignancies [eg, stage I breast cancer or prostate cancer, in-situ carcinoma of the cervix, etc] are not excluded; however, sponsor approval must be obtained before patient is randomized.
- Presence or history of dysphagia or conditions predisposing to dysphagia (eg, uncontrolled gastroesophageal reflux disease [GERD], dyspepsia, etc)
- History of pancreatitis
- Four weeks or less since completion of treatment using an investigational product/device in another clinical study or presence of any unresolved toxicity from previous treatment
- Previous treatment on this study or with a fibroblast growth factor
- Known to be sero-positive for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV)
- Pregnant or breastfeeding women
- Known sensitivity to E. coli derived products
- Compromised ability of the patient to give written informed consent and/or to comply with study procedures
- Refusal to sign an informed consent form to participate in this study, and sign the hospital information release form, if applicable
- Unwilling or unable to complete the patient reported outcome (PRO) questionnaires
- Psychological, social, familial, or geographical reasons that would prevent regular follow-up
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00094861
| Study Director: | MD | Amgen |
| Responsible Party: | Swedish Orphan Biovitrum |
| ClinicalTrials.gov Identifier: | NCT00094861 |
| Other Study ID Numbers: |
20030185 |
| First Posted: | October 27, 2004 Key Record Dates |
| Results First Posted: | March 6, 2014 |
| Last Update Posted: | March 14, 2017 |
| Last Verified: | February 2017 |
|
dysphagia palifermin, KGF chemoradiotherapy NSCLC, non-small cell lung cancer lung cancer |
supportive care clinical trial consolidation chemotherapy radiotherapy |
|
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Deglutition Disorders Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Esophageal Diseases |
Gastrointestinal Diseases Digestive System Diseases Pharyngeal Diseases Otorhinolaryngologic Diseases Paclitaxel Carboplatin Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action |